- Home
- COO vs GMAB Comparison
COO vs GMAB Comparison
Compare COO & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COO
- GMAB
- Stock Information
- Founded
- COO 1980
- GMAB 1999
- Country
- COO United States
- GMAB Denmark
- Employees
- COO N/A
- GMAB N/A
- Industry
- COO Ophthalmic Goods
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- COO Health Care
- GMAB Health Care
- Exchange
- COO Nasdaq
- GMAB Nasdaq
- Market Cap
- COO 16.4B
- GMAB 13.7B
- IPO Year
- COO N/A
- GMAB N/A
- Fundamental
- Price
- COO $69.81
- GMAB $21.56
- Analyst Decision
- COO Strong Buy
- GMAB Buy
- Analyst Count
- COO 9
- GMAB 9
- Target Price
- COO $99.67
- GMAB $39.17
- AVG Volume (30 Days)
- COO 3.2M
- GMAB 1.3M
- Earning Date
- COO 05-29-2025
- GMAB 08-07-2025
- Dividend Yield
- COO N/A
- GMAB N/A
- EPS Growth
- COO 21.77
- GMAB 276.80
- EPS
- COO 2.07
- GMAB 18.36
- Revenue
- COO $3,988,200,000.00
- GMAB $3,230,902,140.00
- Revenue This Year
- COO $6.84
- GMAB $747.74
- Revenue Next Year
- COO $6.49
- GMAB $14.81
- P/E Ratio
- COO $33.73
- GMAB $11.65
- Revenue Growth
- COO 6.88
- GMAB 25.43
- 52 Week Low
- COO $65.00
- GMAB $17.24
- 52 Week High
- COO $112.38
- GMAB $28.56
- Technical
- Relative Strength Index (RSI)
- COO 38.00
- GMAB 49.79
- Support Level
- COO $71.39
- GMAB $22.70
- Resistance Level
- COO $73.47
- GMAB $23.13
- Average True Range (ATR)
- COO 2.32
- GMAB 0.40
- MACD
- COO -0.05
- GMAB -0.04
- Stochastic Oscillator
- COO 56.79
- GMAB 38.67
About COO The Cooper Companies Inc.
CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.